Trials / Completed
CompletedNCT05904470
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
A Phase 2, Open-label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic Hepatitis C Virus (HCV) Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 275 (actual)
- Sponsor
- Atea Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bemnifosbuvir | 550 mg administered orally once a day (QD) for 8 weeks |
| DRUG | Ruzasvir | 180 mg administered orally once a day (QD) for 8 weeks |
Timeline
- Start date
- 2023-05-30
- Primary completion
- 2024-12-09
- Completion
- 2025-01-28
- First posted
- 2023-06-15
- Last updated
- 2025-10-21
- Results posted
- 2025-10-21
Locations
51 sites across 12 countries: United States, Brazil, Canada, India, Mauritius, Moldova, Pakistan, Philippines, Romania, South Africa, South Korea, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05904470. Inclusion in this directory is not an endorsement.